Topics

Human medicines European public assessment report (EPAR): Cabometyx , cabozantinib, Carcinoma, Renal Cell, Date of authorisation: 09/09/2016, Revision: 7, Status: Authorised

11:30 EST 13 Feb 2020 | European Medicines Agency

Human medicines European public assessment report (EPAR): Cabometyx , cabozantinib, Carcinoma, Renal Cell, Date of authorisation: 09/09/2016, Revision: 7, Status: Authorised

Original Article: Human medicines European public assessment report (EPAR): Cabometyx , cabozantinib, Carcinoma, Renal Cell, Date of authorisation: 09/09/2016, Revision: 7, Status: Authorised

NEXT ARTICLE

More From BioPortfolio on "Human medicines European public assessment report (EPAR): Cabometyx , cabozantinib, Carcinoma, Renal Cell, Date of authorisation: 09/09/2016, Revision: 7, Status: Authorised"

Quick Search

Relevant Topic

Renal disease
Chronic kidney disease (CKD), also known as chronic renal disease, is a progressive loss in renal function over a period of months or years. The symptoms of worsening kidney function are non-specific, and might include feeling generally unwell and experi...